Sellas Life Sciences: A Legal Review, a Delayed Readout, and the Gap Between Hope and Hard Data
Published on 09/17/2026 at 16:20 | Editorial boerse-global.de
Two narratives are running side by side at Sellas Life Sciences, and they pull in opposite directions. One is the steady drumbeat of scientific output — abstracts accepted, posters scheduled, preclinical work grinding forward. The other is a quieter, more corrosive story about what happens when a company goes silent at precisely the moment investors expect to hear something.
That tension crystallized on September 13, when Pomerantz LLP confirmed it was reviewing possible claims on behalf of Sellas shareholders. The trigger: reports that the Phase 3 program for galinpepimut-S had hit its pre-specified 80th death event without the company releasing top-line data as anticipated. The dispute, notably, is not about the trial's result. It is about the silence that followed the milestone.
A Familiar Pattern in Biotech
Clinical research is messy. Timelines slip, analyses take time, and statistical thresholds are reached before anyone can say what they mean. But when a pre-defined event count is crossed and the expected disclosure never arrives, a procedural delay can harden into a credibility problem. Pomerantz and firms like it have built a practice around exactly this gap, appearing whenever a share-price decline coincides with a perceived information asymmetry.
Adam Feuerstein, the STAT News columnist, added fuel on Thursday. He voiced skepticism about the REGAL Phase 3 study and predicted a negative outcome for galinpepimut-S in second-remission acute myeloid leukemia. By his account, the study's completion has slipped by nearly a year, and no firm date for results has been set. Feuerstein was explicit that this is his personal forecast, not a reading of published data.
The market did not wait for nuance. Shares changed hands at EUR 9.78, down 4.1% on the day, extending a seven-session slide of 16%. A separate reading of the same stretch put the seven-day decline at 14%, with the stock at EUR 10.05 — either way, the direction is unambiguous.
Should investors sell immediately? Or is it worth buying Sellas Life Sciences?
What the Company Has Actually Said
The only substantive figure Sellas has put forward is an interim snapshot: 78 of 80 relevant events already recorded, with median overall survival of 12.6 months in the treatment arm versus 8 months on standard therapy. That number comes from a preliminary read, not a confirmed final analysis. The entire debate lives in the space between those two things.
For a company with no revenue and a net loss of roughly USD 32.5 million, REGAL carries existential weight. A negative result would strike at the core growth story. Yet the valuation still leans toward optimism: the stock is up 245% year-to-date, buoyed by hopes for a positive readout and ancillary news such as institutional buying. On a price-to-book basis, Sellas trades at 17.1x — far above the biotech sector average of 2.2x, a premium that only a successful trial outcome could justify.
Zoom out, and the picture shifts again. Over twelve months the shares are up 601%, and the year-to-date gain has been cited at 254% in some accounts. Those figures describe a stock that has undergone a fundamental re-rating, driven by clinical progress that dwarfs the recent weeks of losses. The current weakness reads as a correction inside a much larger advance, not a reversal of it.
Science Keeps Moving, Communication Doesn't
While the legal review and the readout delay dominate the conversation, the research engine has not stopped. On September 2, Sellas announced that three abstracts on SLS009 (tambiciclib) for pancreatic cancer had been accepted for an AACR conference — preclinical models, poster presentations, the kind of solid but unspectacular work that appears almost weekly in oncology.
That juxtaposition is the whole story. Scientific progress continues on its own schedule, indifferent to how — or whether — a company communicates it. But investors weigh transparency as heavily as they weigh data. The Pomerantz review is still an inquiry, not a lawsuit. Whether it becomes more depends on how Sellas handles the open questions around galinpepimut-S in the coming weeks.
Until the company names a concrete date for final data, volatility is likely to stay elevated. Feuerstein's call may lack study data behind it, but it lands in an environment already shaped by the legal review — and that is enough to keep the pressure on.
Ad
Sellas Life Sciences Stock: New Analysis - 17 September
Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
